IRB #

STUDY00016365

Title

CrenoGIST– A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene

Principal Investigator

Michael Heinrich

Study Purpose

The purpose of this study is to compare the safety and effects of crenolanib (the study drug) on people and their risk of gastrointestinal stroma tumors (GIST) cancer. In this study, you will get either the study drug or placebo, a pill that looks like the study drug but has no real medicine in it.

Medical Condition(s)

GIST

Eligibility Criteria

>18 years of age diagnosed with GIST with a D842V mutation. Various other tests, procedures, and exams will be done to confirm eligibly.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

For as long as you are seeing benefit from the study drug.

Minors Included

No

Contact

Knight Clinical Trials Information Line
Phone: 503-494-1080
Email: trials@ohsu.edu

Sponsor

Arog Pharmaceuticals Inc.

Recruitment End

08/15/2018

Compensation Provided

No


Go Back